SCHEMBL10189762

SCHEMBL10189762

COc1ccc(-c2[nH]nnc2-c2cc(C)c3c(c2)OCO3)cc1NC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
LMNA P02545 5/20 0.38
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 4/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TGFBR1 P36897 1/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
ADORA3 P0DMS8 3/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HTT P42858 2/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL410873 0.93 KMT2A (0.41) MAPTTP53SMN1; SMN2TSHRMEN1
SCHEMBL10189768 0.86 MAPT (0.36) MAPTTP53SMN1; SMN2TSHRMEN1
SCHEMBL10189741 0.83 MEN1 (0.42) MAPTTP53SMN1; SMN2TSHRMEN1
SCHEMBL10189763 0.82 MAPT (0.40) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL10189760 0.82 ALDH1A1 (0.38) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL10189767 0.81 ERN1 (0.42) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL12339059 0.81 MAPT (0.39) MAPTTP53SMN1; SMN2TSHRMEN1
SCHEMBL15158945 0.81 MAPT (0.38) MAPTSMN1; SMN2TSHRMEN1KMT2A
SCHEMBL10189258 0.80 NPC1 (0.39) MAPTTP53SMN1; SMN2TSHRMEN1
SCHEMBL413893 0.80 ADORA3 (0.46) TP53SMN1; SMN2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 MAPT 95/4885TP53 25/4885SMN1; SMN2 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.